Amarin Corp Plc (AMRN)

[MedResCollab]

"boozeman",

We think the ADA recommendation was prudent given the safety profile of ethyl ester EPA (something you can get OTC), and given the apparent efficacy. But, it does not prove anything, and does not portend the direction FDA will go, who will have access to the entire data, and will scrutinize all aspects of the study, including any evidence suggesting the malabsorption of cardiac medications in the placebo group. Such a pleasure the ADA does not have.

There was a time when the AHA recommended 1 g/d omega-3s for secondary prevention patients. That went away as new evidence came to light.